• Je něco špatně v tomto záznamu ?

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES)

T. Pinter, Z. Klippel, A. Cesas, A. Croitoru, J. Decaestecker, P. Gibbs, Y. Hotko, J. Jassem, G. Kurteva, J. Novotny, S. O'Reilly, T. Salek, M. Reiner, PK. Morrow, MR. Choi, S. Whittaker, C. Blanke,

. 2017 ; 16 (2) : 103-114.e3. [pub] 20160907

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010874

BACKGROUND: Pegfilgrastim's role in reducing the risk of febrile neutropenia (FN) in patients with colorectal cancer (CRC) receiving chemotherapy plus bevacizumab was not previously evaluated in a prospective study. The present phase III, double-blind trial evaluated the efficacy of pegfilgrastim versus placebo in reducing the incidence of grade 3/4 FN in patients with advanced CRC receiving bevacizumab combined with first-line chemotherapy (FOLFOX [leucovorin, 5-fluorouracil, oxaliplatin] or FOLFIRI [leucovorin, 5-fluorouracil, irinotecan]). PATIENTS AND METHODS: Patients aged ≥ 18 years with locally advanced or metastatic CRC were randomized 1:1 to placebo or 6 mg of pegfilgrastim ∼24 hours after receiving chemotherapy plus bevacizumab every 14 days. The study treatment period included 4 cycles, but patients could continue treatment for ≤ 60 months. The primary endpoint was incidence of grade 3/4 FN in the first 4 cycles. The secondary endpoints included the objective response rate (ORR), overall survival, and progression-free survival, analyzed at the end of the long-term follow-up period. RESULTS: A total of 845 patients were randomized from November 2009 to January 2012 (422, pegfilgrastim; 423, placebo). Pegfilgrastim significantly reduced the incidence of grade 3/4 FN in the first 4 treatment cycles (pegfilgrastim, 2.4%; 95% confidence interval [CI], 1.1%-4.3%; placebo, 5.7%; 95% CI, 3.7%-8.3%; odds ratio [OR], 0.41; P = .014). No significant differences were observed between the 2 arms in ORR (OR, 1.15; P = .330), overall survival (hazard ratio, 0.94; P = .440), and progression-free survival (hazard ratio, 0.93; P = .300). CONCLUSION: Pegfilgrastim reduced the FN incidence in patients with advanced CRC receiving chemotherapy and bevacizumab. Administration of pegfilgrastim was tolerable and did not negatively affect the tumor response or survival in this patient population.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010874
003      
CZ-PrNML
005      
20180426100022.0
007      
ta
008      
180404s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.clcc.2016.08.008 $2 doi
035    __
$a (PubMed)28038865
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Pinter, Tamás $u Department of Oncoradiology, Petz Aladár Teaching Hospital, Györ, Hungary. Electronic address: pinterbely@gmail.com.
245    12
$a A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES) / $c T. Pinter, Z. Klippel, A. Cesas, A. Croitoru, J. Decaestecker, P. Gibbs, Y. Hotko, J. Jassem, G. Kurteva, J. Novotny, S. O'Reilly, T. Salek, M. Reiner, PK. Morrow, MR. Choi, S. Whittaker, C. Blanke,
520    9_
$a BACKGROUND: Pegfilgrastim's role in reducing the risk of febrile neutropenia (FN) in patients with colorectal cancer (CRC) receiving chemotherapy plus bevacizumab was not previously evaluated in a prospective study. The present phase III, double-blind trial evaluated the efficacy of pegfilgrastim versus placebo in reducing the incidence of grade 3/4 FN in patients with advanced CRC receiving bevacizumab combined with first-line chemotherapy (FOLFOX [leucovorin, 5-fluorouracil, oxaliplatin] or FOLFIRI [leucovorin, 5-fluorouracil, irinotecan]). PATIENTS AND METHODS: Patients aged ≥ 18 years with locally advanced or metastatic CRC were randomized 1:1 to placebo or 6 mg of pegfilgrastim ∼24 hours after receiving chemotherapy plus bevacizumab every 14 days. The study treatment period included 4 cycles, but patients could continue treatment for ≤ 60 months. The primary endpoint was incidence of grade 3/4 FN in the first 4 cycles. The secondary endpoints included the objective response rate (ORR), overall survival, and progression-free survival, analyzed at the end of the long-term follow-up period. RESULTS: A total of 845 patients were randomized from November 2009 to January 2012 (422, pegfilgrastim; 423, placebo). Pegfilgrastim significantly reduced the incidence of grade 3/4 FN in the first 4 treatment cycles (pegfilgrastim, 2.4%; 95% confidence interval [CI], 1.1%-4.3%; placebo, 5.7%; 95% CI, 3.7%-8.3%; odds ratio [OR], 0.41; P = .014). No significant differences were observed between the 2 arms in ORR (OR, 1.15; P = .330), overall survival (hazard ratio, 0.94; P = .440), and progression-free survival (hazard ratio, 0.93; P = .300). CONCLUSION: Pegfilgrastim reduced the FN incidence in patients with advanced CRC receiving chemotherapy and bevacizumab. Administration of pegfilgrastim was tolerable and did not negatively affect the tumor response or survival in this patient population.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
650    _2
$a bevacizumab $x aplikace a dávkování $7 D000068258
650    _2
$a kamptothecin $x aplikace a dávkování $x škodlivé účinky $x analogy a deriváty $7 D002166
650    _2
$a kolorektální nádory $x farmakoterapie $x patologie $7 D015179
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a febrilní neutropenie $x chemicky indukované $x epidemiologie $x prevence a kontrola $7 D064147
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a filgrastim $x aplikace a dávkování $7 D000069585
650    _2
$a fluoruracil $x aplikace a dávkování $x škodlivé účinky $7 D005472
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a incidence $7 D015994
650    _2
$a leukovorin $x aplikace a dávkování $x škodlivé účinky $7 D002955
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a organoplatinové sloučeniny $x aplikace a dávkování $x škodlivé účinky $7 D009944
650    _2
$a polyethylenglykoly $x aplikace a dávkování $7 D011092
650    _2
$a proporcionální rizikové modely $7 D016016
650    _2
$a prospektivní studie $7 D011446
650    _2
$a míra přežití $7 D015996
650    _2
$a vaskulární endoteliální růstový faktor A $x antagonisté a inhibitory $7 D042461
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Klippel, Zandra $u Clinical Development, Amgen Inc, Thousand Oaks, CA.
700    1_
$a Cesas, Alvydas $u Department of Medical Oncology, Klaipeda University Hospital, Klaipeda, Lithuania.
700    1_
$a Croitoru, Adina $u Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania.
700    1_
$a Decaestecker, Jochen $u Department of Oncology, AZ Delta Hospital, Roeselare, Belgium.
700    1_
$a Gibbs, Peter $u Department of Oncology, The Western Hospital, Footscray, Victoria, Australia.
700    1_
$a Hotko, Yevhen $u Uzhgorod Regional Oncology Dispensary, Uzhgorod National University, Uzhgorod, Ukraine.
700    1_
$a Jassem, Jacek $u Department of Oncology and Radiotherapy, Medical University Gdansk, Gdansk, Poland.
700    1_
$a Kurteva, Galina $u Clinic of Medical Oncology, Specialized Hospital for Active Treatment in Oncology Sofia, Sofia, Bulgaria.
700    1_
$a Novotny, Jan $u Department of Oncology, Institute of Oncology and Rehabilitation, Nová Ves pod Pleší, Czech Republic.
700    1_
$a O'Reilly, Seamus $u Department of Medical Oncology, Ireland Cooperative Oncology Research Group, Dublin, Ireland.
700    1_
$a Salek, Tomas $u Department of Clinical Oncology, National Cancer Institute, Bratislava, Slovakia.
700    1_
$a Reiner, Maureen $u Global Biostatistical Sciences, Amgen Inc, Thousand Oaks, CA.
700    1_
$a Morrow, Phuong Khanh $u Clinical Development, Amgen Inc, Thousand Oaks, CA.
700    1_
$a Choi, Mi Rim $u Clinical Development, Amgen Inc, Thousand Oaks, CA.
700    1_
$a Whittaker, Sadie $u Clinical Development, Amgen Inc, Thousand Oaks, CA.
700    1_
$a Blanke, Charles $u Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Sciences University, Portland, OR.
773    0_
$w MED00007435 $t Clinical colorectal cancer $x 1938-0674 $g Roč. 16, č. 2 (2017), s. 103-114.e3
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28038865 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180426100132 $b ABA008
999    __
$a ok $b bmc $g 1288359 $s 1007686
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 16 $c 2 $d 103-114.e3 $e 20160907 $i 1938-0674 $m Clinical colorectal cancer $n Clin Colorectal Cancer $x MED00007435
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace